Temporal dynamics and drivers of durable HIV viral load suppression and persistent high‐ and low‐level viraemia during Universal Test and Treat scale‐up in Uganda: a population‐based study
Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up. Methods...
Saved in:
Published in | Journal of the International AIDS Society Vol. 27; no. 2; pp. e26200 - n/a |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
John Wiley & Sons, Inc
01.02.2024
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Introduction
Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up.
Methods
In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations.
Results
Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%).
Conclusions
Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control. |
---|---|
AbstractList | Introduction
Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up.
Methods
In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations.
Results
Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%).
Conclusions
Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control. IntroductionPopulation-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale-up.MethodsIn 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200–999 copies/ml) or high-level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit-pairs; ∼18-month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow-up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations.ResultsOverall, 3080 participants contributed 4604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow-up, 91.3% of which was high-level viraemia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viraemia self-reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high-level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40- to 49-year-olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non-marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high-level viraemia was highest among males <30 years (32.0%).ConclusionsFollowing universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high-level viraemia for ≥12 months and reported higher-risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control. Population-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale-up. In 2015-2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200-999 copies/ml) or high-level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit-pairs; ∼18-month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow-up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Overall, 3080 participants contributed 4604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow-up, 91.3% of which was high-level viraemia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viraemia self-reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high-level viraemia varied substantially across communities and was significantly elevated among young persons aged 15-29 years (vs. 40- to 49-year-olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21-3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87-3.07), persons reporting inconsistent condom use with non-marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10-1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03-1.16). The prevalence of persistent high-level viraemia was highest among males <30 years (32.0%). Following universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high-level viraemia for ≥12 months and reported higher-risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control. Abstract Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up. Methods In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Results Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%). Conclusions Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control. Introduction: Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up. Methods: In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Results: Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%). Conclusions: Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control. In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%). Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control. Population-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale-up.INTRODUCTIONPopulation-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale-up.In 2015-2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200-999 copies/ml) or high-level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit-pairs; ∼18-month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow-up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations.METHODSIn 2015-2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200-999 copies/ml) or high-level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit-pairs; ∼18-month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow-up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations.Overall, 3080 participants contributed 4604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow-up, 91.3% of which was high-level viraemia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viraemia self-reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high-level viraemia varied substantially across communities and was significantly elevated among young persons aged 15-29 years (vs. 40- to 49-year-olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21-3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87-3.07), persons reporting inconsistent condom use with non-marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10-1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03-1.16). The prevalence of persistent high-level viraemia was highest among males <30 years (32.0%).RESULTSOverall, 3080 participants contributed 4604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow-up, 91.3% of which was high-level viraemia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viraemia self-reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high-level viraemia varied substantially across communities and was significantly elevated among young persons aged 15-29 years (vs. 40- to 49-year-olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21-3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87-3.07), persons reporting inconsistent condom use with non-marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10-1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03-1.16). The prevalence of persistent high-level viraemia was highest among males <30 years (32.0%).Following universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high-level viraemia for ≥12 months and reported higher-risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.CONCLUSIONSFollowing universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high-level viraemia for ≥12 months and reported higher-risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control. |
Audience | Academic |
Author | Rosen, Joseph Gregory Kisakye, Alice Ndyanabo, Anthony Patel, Eshan U. Ssekubugu, Robert Kigozi, Godfrey Kennedy, Caitlin E. Grabowski, Mary Kathryn Ssekasanvu, Joseph Reynolds, Steven J. Chang, Larry W. Galiwango, Ronald M. Rucinski, Katherine B. Nalugoda, Fred Kagaayi, Joseph Mills, Lisa A. Ratmann, Oliver Kabatesi, Donna Tobian, Aaron A. R. Quinn, Thomas C. Ssempijja, Victor Nakigozi, Gertrude Nelson, Lisa J. |
Author_xml | – sequence: 1 givenname: Joseph Gregory orcidid: 0000-0003-4991-4033 surname: Rosen fullname: Rosen, Joseph Gregory email: jrosen72@jhu.edu organization: Johns Hopkins Bloomberg School of Public Health – sequence: 2 givenname: Robert surname: Ssekubugu fullname: Ssekubugu, Robert organization: Rakai Health Sciences Program – sequence: 3 givenname: Larry W. surname: Chang fullname: Chang, Larry W. organization: Johns Hopkins Bloomberg School of Public Health – sequence: 4 givenname: Victor orcidid: 0000-0003-2609-6525 surname: Ssempijja fullname: Ssempijja, Victor organization: Frederick National Laboratory for Cancer Research – sequence: 5 givenname: Ronald M. surname: Galiwango fullname: Galiwango, Ronald M. organization: Rakai Health Sciences Program – sequence: 6 givenname: Joseph surname: Ssekasanvu fullname: Ssekasanvu, Joseph organization: Rakai Health Sciences Program – sequence: 7 givenname: Anthony surname: Ndyanabo fullname: Ndyanabo, Anthony organization: Rakai Health Sciences Program – sequence: 8 givenname: Alice surname: Kisakye fullname: Kisakye, Alice organization: Rakai Health Sciences Program – sequence: 9 givenname: Gertrude surname: Nakigozi fullname: Nakigozi, Gertrude organization: Rakai Health Sciences Program – sequence: 10 givenname: Katherine B. orcidid: 0000-0002-9858-5953 surname: Rucinski fullname: Rucinski, Katherine B. organization: Johns Hopkins Bloomberg School of Public Health – sequence: 11 givenname: Eshan U. surname: Patel fullname: Patel, Eshan U. organization: Johns Hopkins Bloomberg School of Public Health – sequence: 12 givenname: Caitlin E. orcidid: 0000-0001-6820-063X surname: Kennedy fullname: Kennedy, Caitlin E. organization: Rakai Health Sciences Program – sequence: 13 givenname: Fred surname: Nalugoda fullname: Nalugoda, Fred organization: Rakai Health Sciences Program – sequence: 14 givenname: Godfrey surname: Kigozi fullname: Kigozi, Godfrey organization: Rakai Health Sciences Program – sequence: 15 givenname: Oliver surname: Ratmann fullname: Ratmann, Oliver organization: Imperial College – sequence: 16 givenname: Lisa J. surname: Nelson fullname: Nelson, Lisa J. organization: Centers for Disease Control and Prevention – sequence: 17 givenname: Lisa A. surname: Mills fullname: Mills, Lisa A. organization: Centers for Disease Control and Prevention – sequence: 18 givenname: Donna surname: Kabatesi fullname: Kabatesi, Donna organization: Centers for Disease Control and Prevention – sequence: 19 givenname: Aaron A. R. surname: Tobian fullname: Tobian, Aaron A. R. organization: Johns Hopkins School of Medicine – sequence: 20 givenname: Thomas C. surname: Quinn fullname: Quinn, Thomas C. organization: National Institutes of Health – sequence: 21 givenname: Joseph surname: Kagaayi fullname: Kagaayi, Joseph organization: Rakai Health Sciences Program – sequence: 22 givenname: Steven J. surname: Reynolds fullname: Reynolds, Steven J. organization: National Institutes of Health – sequence: 23 givenname: Mary Kathryn orcidid: 0000-0002-4451-3436 surname: Grabowski fullname: Grabowski, Mary Kathryn organization: Johns Hopkins School of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38332519$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kstuEzEUhkeoiF5gwwMgS0gIIaXYnvFcuosqoEGV2KRsrRP7TOLIsQd7plV2PAIPxZPwJDiTUlpUIS9sHX__b5_LcXbgvMMse8noKaOUv18b4Ke85JQ-yY5YJeoJLwU_uHc-zI5jXFNa8rponmWHeZ3nXLDmKPs5x03nA1iitw42RkUCThMdzDWGSHxL9BBgYZFczL6Sa7MjrQdN4tB1AWM03o2KLuEm9uh6sjLL1a_vP8aw9TfpaPEa7ajGjYGdpXFLcuXGR5LjHGM_4vOA0JOowGKSDR0xjlwt0w2cESCd7wYLfXoyXS4gYvpGP-jt8-xpCzbii9v9JLv6-GF-fjG5_PJpdj69nCghCjrRoFsQwEslWgU5S4WhikJVFFhUulQt0zpnCijQWrAW60UDXDcNq1ihNUB-ks32vtrDWnbBbCBspQcjx4APSwmhN8qipFSUbYklipYWomSNqFRRVTVWSkOuaPJ6u_fqgv82pPzlxkSF1oJDP0TJG140TVmIOqGv_0HXfgguZZqonNXJn5Z_qWUqnjSu9X0AtTOV06phtGS04omaPEIt0WHqbBqr1qTwA_70ET4tnTqpHhW8uSdYIdh-Fb0ddl2LD8FXt1kNiw3qu3L-mc0EvNsDKvgYA7Z3CKNyN_hyN_hyHPwEsz18k_6z_Q8pP8-mfK_5DYcRB6Y |
Cites_doi | 10.1080/17441692.2015.1074715 10.1056/NEJMoa1812281 10.1186/s12879-017-2680-6 10.1056/NEJMoa1814556 10.1002/jia2.25517 10.1097/QAI.0000000000002811 10.1016/j.jviromet.2013.04.003 10.1093/aje/kwn164 10.1097/QAD.0000000000002538 10.1097/QAI.0000000000000489 10.7448/IAS.20.1.21590 10.1097/EDE.0000000000000409 10.1086/498515 10.1016/S2352-3018(21)00069-2 10.1155/2013/470245 10.1016/S2352-3018(17)30205-9 10.1097/QAD.0000000000003388 10.1038/s41467-020-14636-y 10.1371/journal.pmed.1001610 10.1111/hiv.13203 10.1136/bmjgh-2021-007312 10.1097/QAD.0000000000001536 10.1016/S2352-3018(19)30402-3 10.1002/jia2.26033 10.1007/s11904-020-00492-4 10.1097/MD.0000000000003985 10.1080/09540121.2019.1595509 10.7448/IAS.19.1.21106 10.1371/journal.pmed.1003042 10.1093/infdis/jir353 10.1016/S2214-109X(22)00413-2 10.1056/NEJMoa1809866 10.15585/mmwr.mm6948a1 10.1002/jia2.25048 10.1111/j.0006-341X.2001.00120.x 10.1002/jia2.26005 10.1016/S2352-3018(19)30190-0 10.1177/019251396017003001 10.1093/infdis/jiab021 10.1097/QAD.0000000000002989 10.1093/cid/ciaa413 10.1016/j.drugalcdep.2021.109005 10.1056/NEJMoa1702150 10.1371/journal.pone.0256865 10.1016/S2352-3018(20)30359-3 10.1016/S0140-6736(23)00877-2 10.1097/QAI.0000000000002508 10.1007/s10461-022-03582-z 10.1016/S2352-3018(16)30034-0 10.1056/NEJMp1710608 10.1016/S2352-3018(19)30407-2 |
ContentType | Journal Article |
Copyright | 2024 The Authors. published by John Wiley & Sons Ltd on behalf of International AIDS Society. 2024 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. COPYRIGHT 2024 John Wiley & Sons, Inc. 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024 The Authors. published by John Wiley & Sons Ltd on behalf of International AIDS Society. – notice: 2024 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. – notice: COPYRIGHT 2024 John Wiley & Sons, Inc. – notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 DOA |
DOI | 10.1002/jia2.26200 |
DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 1758-2652 |
EndPage | n/a |
ExternalDocumentID | oai_doaj_org_article_0056f6e6e5f04561957c4778e7cda3c0 A791061072 38332519 10_1002_jia2_26200 JIA226200 |
Genre | article Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | Uganda Lake Victoria Africa |
GeographicLocations_xml | – name: Uganda – name: Lake Victoria – name: Africa |
GrantInformation_xml | – fundername: National Institute of Allergy and Infectious Diseases funderid: U01AI100031; U01AI075115; R01AI110324; R01AI128779; R01AI123002; R01AI143333; R01AI155080; T32AI102623 – fundername: National Institute of Mental Health funderid: R01MH105313; F31MH126796; K01MH129226 – fundername: National Cancer Institute funderid: 75N91019D00024 – fundername: National Institute on Drug Abuse funderid: F31DA054849 – fundername: U.S. President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention funderid: NU2GGH00081 – fundername: NIAID NIH HHS grantid: R01 AI155080 – fundername: NIMH NIH HHS grantid: K01 MH129226 – fundername: NIAID NIH HHS grantid: U01 AI075115 – fundername: NIAID NIH HHS grantid: R01 AI128779 – fundername: NIMH NIH HHS grantid: F31MH126796 – fundername: NIAID NIH HHS grantid: T32 AI102623 – fundername: NCI NIH HHS grantid: 75N91019D00024 – fundername: NIAID NIH HHS grantid: R01 AI143333 – fundername: NIMH NIH HHS grantid: K01MH129226 – fundername: NIDA NIH HHS grantid: F31DA054849 |
GroupedDBID | --- 0R~ 1OC 24P 29L 2VQ 2WC 4.4 53G 5GY 5VS 7X7 88E 8FI 8FJ AAMMB ABDBF ABUWG ACCMX ACGFO ACGFS ACUHS ACXQS ADBBV ADKYN ADPDF ADRAZ ADUKV ADZMN AEFGJ AEGXH AENEX AEUYN AFKRA AGXDD AHBYD AHMBA AIAGR AIDQK AIDYY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AOIJS AVUZU BAWUL BCNDV BENPR BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR IOF ITC KQ8 M1P M48 M~E N8Y O5R O5S O9- OK1 OVD OVEED P2P PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS ROL RPM RSV SMD SOJ SV3 TEORI TR2 TUS UKHRP AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE CITATION CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7XB 8FK AZQEC COVID DWQXO K9. PKEHL PQEST PQUKI PRINS WIN 7X8 PUEGO |
ID | FETCH-LOGICAL-c5540-dadfa5a26c5fca316520c0a744e47d6cf1dd31ca0a0851fe8b9a2d991714ddaa3 |
IEDL.DBID | M48 |
ISSN | 1758-2652 |
IngestDate | Wed Aug 27 01:04:21 EDT 2025 Fri Jul 11 16:49:17 EDT 2025 Wed Aug 13 08:37:45 EDT 2025 Tue Jun 17 22:09:23 EDT 2025 Fri Jun 13 00:06:11 EDT 2025 Tue Jun 10 21:02:46 EDT 2025 Thu May 22 21:24:07 EDT 2025 Mon Jul 21 06:02:02 EDT 2025 Tue Jul 01 03:55:14 EDT 2025 Sun Jul 06 04:45:27 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | HIV treatment HIV viraemia prospective cohort sub-Saharan Africa Treat All antiretroviral therapy |
Language | English |
License | Attribution 2024 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5540-dadfa5a26c5fca316520c0a744e47d6cf1dd31ca0a0851fe8b9a2d991714ddaa3 |
Notes | These authors contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-2609-6525 0000-0002-4451-3436 0000-0002-9858-5953 0000-0003-4991-4033 0000-0001-6820-063X |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1002/jia2.26200 |
PMID | 38332519 |
PQID | 2931845606 |
PQPubID | 55048 |
PageCount | 14 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_0056f6e6e5f04561957c4778e7cda3c0 proquest_miscellaneous_2924996458 proquest_journals_2931845606 gale_infotracmisc_A791061072 gale_infotracgeneralonefile_A791061072 gale_infotracacademiconefile_A791061072 gale_healthsolutions_A791061072 pubmed_primary_38332519 crossref_primary_10_1002_jia2_26200 wiley_primary_10_1002_jia2_26200_JIA226200 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | February 2024 2024-02-00 20240201 2024-02-01 |
PublicationDateYYYYMMDD | 2024-02-01 |
PublicationDate_xml | – month: 02 year: 2024 text: February 2024 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Geneva |
PublicationTitle | Journal of the International AIDS Society |
PublicationTitleAlternate | J Int AIDS Soc |
PublicationYear | 2024 |
Publisher | John Wiley & Sons, Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley |
References | 2021; 8 2017; 20 1996; 17 2019; 6 2016; 19 2021; 88 2021; 223 2019; 31 2020; 85 2023; 37 2021; 228 2020; 17 2022; 23 2023; 402 2022; 25 2016; 95 2022; 26 2020; 34 2020; 11 2008; 168 2021; 72 2017; 377 2018; 21 2019; 381 2011; 204 2015; 68 2021; 35 2020; 7 2017; 31 2021; 16 2006; 42 2018; 5 2016; 3 2022 2013; 2013 2021 2017; 17 2022; 7 2017; 12 2020; 69 2020; 23 2014 2022; 10 2013; 192 2001; 57 2016; 27 2014; 11 e_1_2_12_4_1 e_1_2_12_6_1 e_1_2_12_19_1 e_1_2_12_2_1 e_1_2_12_17_1 e_1_2_12_38_1 e_1_2_12_20_1 e_1_2_12_41_1 e_1_2_12_22_1 e_1_2_12_43_1 e_1_2_12_24_1 e_1_2_12_45_1 e_1_2_12_26_1 e_1_2_12_47_1 e_1_2_12_28_1 e_1_2_12_49_1 e_1_2_12_31_1 e_1_2_12_52_1 e_1_2_12_33_1 e_1_2_12_54_1 e_1_2_12_35_1 e_1_2_12_56_1 e_1_2_12_37_1 e_1_2_12_14_1 e_1_2_12_12_1 e_1_2_12_8_1 e_1_2_12_10_1 Ssempijja V (e_1_2_12_53_1) 2022; 25 e_1_2_12_50_1 e_1_2_12_3_1 e_1_2_12_5_1 e_1_2_12_18_1 e_1_2_12_16_1 e_1_2_12_39_1 e_1_2_12_42_1 e_1_2_12_21_1 e_1_2_12_44_1 e_1_2_12_23_1 e_1_2_12_46_1 e_1_2_12_25_1 e_1_2_12_48_1 e_1_2_12_40_1 e_1_2_12_27_1 e_1_2_12_29_1 e_1_2_12_30_1 e_1_2_12_32_1 e_1_2_12_55_1 e_1_2_12_34_1 e_1_2_12_57_1 e_1_2_12_36_1 e_1_2_12_15_1 e_1_2_12_13_1 e_1_2_12_11_1 e_1_2_12_7_1 e_1_2_12_51_1 e_1_2_12_9_1 37398460 - medRxiv. 2023 Jun 16:2023.06.15.23291445. doi: 10.1101/2023.06.15.23291445. |
References_xml | – volume: 402 start-page: 464 issue: 10400 year: 2023 end-page: 471 article-title: The risk of sexual transmission of HIV in individuals with low‐level HIV viraemia: a systematic review publication-title: Lancet – volume: 5 start-page: e116 issue: 3 year: 2018 end-page: e125 article-title: Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open‐label, community cluster randomised trial publication-title: Lancet HIV – volume: 7 issue: 1 year: 2022 article-title: Mitigating the effects of COVID‐19 on HIV treatment and care in Lusaka, Zambia: a before‐after cohort study using mixed effects regression publication-title: BMJ Glob Health – volume: 34 start-page: 1065 issue: 7 year: 2020 end-page: 1074 article-title: Clinic‐level and individual‐level factors that influence HIV viral suppression in adolescents and young adults: a national survey in Kenya publication-title: AIDS – volume: 25 issue: S3 year: 2022 article-title: Population trends in HIV service delivery, viral suppression, and incidence before and during the COVID‐19 era in Rakai, Uganda publication-title: J Int AIDS Soc – volume: 23 issue: S2 year: 2020 article-title: Gendered health institutions: examining the organization of health services and men's use of HIV testing in Malawi publication-title: J Int AIDS Soc – volume: 25 issue: 11 year: 2022 article-title: Protecting the gains: analysis of HIV treatment and service delivery programme data and interventions implemented in 19 African countries during COVID‐19 publication-title: J Int AIDS Soc – volume: 17 start-page: 249 issue: 3 year: 2020 end-page: 258 article-title: Integrating and interpreting findings from the latest treatment as prevention trials publication-title: Curr HIV/AIDS Rep – year: 2021 – volume: 88 start-page: 448 issue: 5 year: 2021 end-page: 456 article-title: Impact of the COVID‐19 pandemic on use of HIV care, antiretroviral therapy adherence, and viral suppression: an observational cohort study from Uganda publication-title: J Acquir Immune Defic Syndr – volume: 21 issue: 1 year: 2018 article-title: Comparative assessment of five trials of universal HIV testing and treatment in sub‐Saharan Africa publication-title: J Int AIDS Soc – volume: 57 start-page: 120 issue: 1 year: 2001 end-page: 125 article-title: Akaike's information criterion in generalized estimating equations publication-title: Biometrics – volume: 95 issue: 28 year: 2016 article-title: Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource‐limited settings publication-title: Medicine (Baltimore) – volume: 20 start-page: 21590 issue: 1 year: 2017 end-page: 21598 article-title: Human immunodeficiency virus care cascade among sub‐populations in Rakai, Uganda: an observational study publication-title: J Int AIDS Soc – year: 2014 – volume: 6 start-page: e680 issue: 10 year: 2019 end-page: e687 article-title: Impact of combination HIV interventions on HIV incidence in hyperendemic fishing communities in Uganda: a prospective cohort study publication-title: Lancet HIV – volume: 16 issue: 9 year: 2021 article-title: Migration in Namibia and its association with HIV acquisition and treatment outcomes publication-title: PLoS One – volume: 11 issue: 3 year: 2014 article-title: The role of viral introductions in sustaining community‐based HIV epidemics in rural Uganda: evidence from spatial clustering, phylogenetics, and egocentric transmission models publication-title: PLoS Med – volume: 7 start-page: e229 issue: 4 year: 2020 end-page: e237 article-title: Point‐of‐care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open‐label, non‐inferiority, randomised controlled trial publication-title: Lancet HIV – volume: 42 start-page: 136 issue: 1 year: 2006 end-page: 144 article-title: Virological control during the first 6–18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV‐infected patients: a Danish, population‐based, 6‐year follow‐up study publication-title: Clin Infect Dis – volume: 72 start-page: 2079 issue: 12 year: 2021 end-page: 2086 article-title: All‐cause mortality and serious non‐AIDS events in adults with low‐level human immunodeficiency virus viremia during combination antiretroviral therapy: results from a Swedish nationwide observational study publication-title: Clin Infect Dis – year: 2022 – volume: 10 start-page: e1815 issue: 12 year: 2022 end-page: e1824 article-title: Low‐level viraemia among people living with HIV in Nigeria: a retrospective longitudinal cohort study publication-title: Lancet Glob Health – volume: 17 issue: 3 year: 2020 article-title: Mapping and characterising areas with high levels of HIV transmission in sub‐Saharan Africa: a geospatial analysis of national survey data publication-title: PLoS Med – volume: 35 start-page: 1835 issue: 11 year: 2021 end-page: 1843 article-title: Household wealth and HIV incidence over time, rural Uganda, 1994–2018 publication-title: AIDS – volume: 12 start-page: 1033 issue: 8 year: 2017 end-page: 1050 article-title: Mobility among youth in Rakai, Uganda: trends, characteristics, and associations with behavioural risk factors for HIV publication-title: Glob Public Health – volume: 223 start-page: 1150 issue: 7 year: 2021 end-page: 1160 article-title: Prevalence and predictors of persistent human immunodeficiency virus viremia and viral rebound after universal test and treat: a population‐based study publication-title: J Infect Dis – volume: 377 start-page: 2154 issue: 22 year: 2017 end-page: 2166 article-title: Combination HIV prevention and HIV incidence in Uganda publication-title: N Engl J Med – volume: 204 start-page: 515 issue: 4 year: 2011 end-page: 520 article-title: Antiretroviral drug resistance in HIV‐1–infected patients experiencing persistent low‐level viremia during first‐line therapy publication-title: J Infect Dis – volume: 192 start-page: 25 issue: 1–2 year: 2013 end-page: 27 article-title: Evaluation of current rapid HIV test algorithms in Rakai, Uganda publication-title: J Virol Methods – volume: 26 start-page: 2387 issue: 7 year: 2022 end-page: 2396 article-title: Cyclical engagement in HIV care: a qualitative study of clinic transfers to re‐enter HIV care in Cape Town, South Africa publication-title: AIDS Behav – volume: 23 start-page: 474 issue: 5 year: 2022 end-page: 484 article-title: Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first‐line HIV treatment in Uganda and South Africa publication-title: HIV Med – volume: 377 start-page: 1605 issue: 17 year: 2017 end-page: 1607 article-title: HIV drug resistance — an emerging threat to epidemic control publication-title: N Engl J Med – volume: 7 start-page: e209 issue: 3 year: 2020 end-page: e214 article-title: HIV transmission and source‐sink dynamics in sub‐Saharan Africa publication-title: Lancet HIV – volume: 17 start-page: 582 issue: 1 year: 2017 article-title: Rates of switching to second‐line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV‐infected adults with virologic failure in Rakai, Uganda publication-title: BMC Infect Dis – volume: 85 start-page: 571 issue: 5 year: 2020 end-page: 578 article-title: Improved viral suppression with streamlined care in the SEARCH study publication-title: J Acquir Immune Defic Syndr – volume: 31 start-page: 1435 issue: 11 year: 2019 end-page: 1446 article-title: A scoping review on the role of masculine norms in men's engagement in the HIV care continuum in sub‐Saharan Africa publication-title: AIDS Care – volume: 381 start-page: 207 issue: 3 year: 2019 end-page: 218 article-title: Effect of universal testing and treatment on HIV incidence — HPTN 071 (PopART) publication-title: N Engl J Med – volume: 17 start-page: 283 issue: 3 year: 1996 end-page: 316 article-title: The revised Conflict Tactics Scales (CTS2): development and preliminary psychometric data publication-title: J Fam Issues – volume: 168 start-page: 656 issue: 6 year: 2008 end-page: 664 article-title: Constructing inverse probability weights for marginal structural models publication-title: Am J Epidemiol – volume: 68 start-page: 413 issue: 4 year: 2015 end-page: 419 article-title: Impact of age on retention in care and viral suppression publication-title: J Acquir Immune Defic Syndr – volume: 31 start-page: 1637 issue: 11 year: 2017 end-page: 1639 article-title: HIV drug resistance in Africa: an emerging problem that deserves urgent attention publication-title: AIDS – volume: 8 start-page: e429 issue: 7 year: 2021 end-page: e439 article-title: Age patterns of HIV incidence in eastern and southern Africa: a modelling analysis of observational population‐based cohort studies publication-title: Lancet HIV – volume: 19 issue: 1 year: 2016 article-title: Marked sex differences in all‐cause mortality on antiretroviral therapy in low‐ and middle‐income countries: a systematic review and meta‐analysis publication-title: J Int AIDS Soc – volume: 11 start-page: 976 issue: 1 year: 2020 article-title: Migration, hotspots, and dispersal of HIV infection in Rakai, Uganda publication-title: Nat Commun – volume: 69 start-page: 1801 issue: 48 year: 2020 end-page: 1806 article-title: Sex differences in HIV testing ‐ 20 PEPFAR‐supported sub‐Saharan African countries, 2019 publication-title: MMWR Morb Mortal Wkly Rep – volume: 2013 year: 2013 article-title: A qualitative study of barriers to enrollment into free HIV care: perspectives of never‐in‐care HIV‐positive patients and providers in Rakai, Uganda publication-title: Biomed Res Int – volume: 3 start-page: e388 issue: 8 year: 2016 end-page: e396 article-title: Heterogeneity of the HIV epidemic in agrarian, trading, and fishing communities in Rakai, Uganda: an observational epidemiological study publication-title: Lancet HIV – volume: 27 start-page: 91 issue: 1 year: 2016 end-page: 97 article-title: Selection bias due to loss to follow up in cohort studies publication-title: Epidemiology – volume: 381 start-page: 219 issue: 3 year: 2019 end-page: 229 article-title: HIV testing and treatment with the use of a community health approach in rural Africa publication-title: N Engl J Med – volume: 381 start-page: 207 issue: 3 year: 2019 end-page: 218 article-title: Impact of a universal testing and treatment intervention on HIV incidence in Zambia and South Africa: results of the HPTN 071 (PopART) community‐randomized trial publication-title: N Engl J Med – volume: 37 start-page: 113 issue: 1 year: 2023 article-title: Male partner age, viral load, and HIV infection in adolescent girls and young women: evidence from eight sub‐Saharan African countries publication-title: AIDS – volume: 8 start-page: e158 issue: 3 year: 2021 end-page: e165 article-title: The impact of the COVID‐19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis publication-title: Lancet HIV – volume: 381 start-page: 230 issue: 3 year: 2019 end-page: 242 article-title: Universal testing, expanded treatment, and incidence of HIV infection in Botswana publication-title: N Engl J Med – volume: 228 year: 2021 article-title: Alcohol use and alcohol‐related consequences are associated with not being virally suppressed among persons living with HIV in the Rakai region of Uganda publication-title: Drug Alcohol Depend – volume: 25 issue: 4 year: 2022 article-title: Progress towards the UNAIDS 90‐90‐90 targets among persons aged 50 and older living with HIV in 13 African countries publication-title: J Int AIDS Soc – ident: e_1_2_12_21_1 doi: 10.1080/17441692.2015.1074715 – ident: e_1_2_12_3_1 doi: 10.1056/NEJMoa1812281 – ident: e_1_2_12_37_1 doi: 10.1186/s12879-017-2680-6 – ident: e_1_2_12_9_1 doi: 10.1056/NEJMoa1814556 – ident: e_1_2_12_41_1 doi: 10.1002/jia2.25517 – ident: e_1_2_12_50_1 doi: 10.1097/QAI.0000000000002811 – ident: e_1_2_12_5_1 doi: 10.1056/NEJMoa1814556 – ident: e_1_2_12_22_1 doi: 10.1016/j.jviromet.2013.04.003 – ident: e_1_2_12_54_1 doi: 10.1093/aje/kwn164 – ident: e_1_2_12_43_1 doi: 10.1097/QAD.0000000000002538 – ident: e_1_2_12_56_1 doi: 10.1097/QAI.0000000000000489 – ident: e_1_2_12_44_1 doi: 10.7448/IAS.20.1.21590 – ident: e_1_2_12_55_1 doi: 10.1097/EDE.0000000000000409 – ident: e_1_2_12_12_1 doi: 10.1086/498515 – ident: e_1_2_12_35_1 doi: 10.1016/S2352-3018(21)00069-2 – ident: e_1_2_12_47_1 doi: 10.1155/2013/470245 – ident: e_1_2_12_2_1 doi: 10.1016/S2352-3018(17)30205-9 – ident: e_1_2_12_46_1 doi: 10.1097/QAD.0000000000003388 – ident: e_1_2_12_17_1 doi: 10.1038/s41467-020-14636-y – ident: e_1_2_12_32_1 doi: 10.1371/journal.pmed.1001610 – ident: e_1_2_12_38_1 doi: 10.1111/hiv.13203 – ident: e_1_2_12_52_1 doi: 10.1136/bmjgh-2021-007312 – ident: e_1_2_12_36_1 doi: 10.1097/QAD.0000000000001536 – ident: e_1_2_12_39_1 doi: 10.1016/S2352-3018(19)30402-3 – ident: e_1_2_12_49_1 doi: 10.1002/jia2.26033 – ident: e_1_2_12_11_1 doi: 10.1007/s11904-020-00492-4 – ident: e_1_2_12_19_1 doi: 10.1097/MD.0000000000003985 – ident: e_1_2_12_40_1 doi: 10.1080/09540121.2019.1595509 – ident: e_1_2_12_30_1 doi: 10.7448/IAS.19.1.21106 – ident: e_1_2_12_33_1 doi: 10.1371/journal.pmed.1003042 – ident: e_1_2_12_18_1 doi: 10.1093/infdis/jir353 – ident: e_1_2_12_20_1 doi: 10.1016/S2214-109X(22)00413-2 – ident: e_1_2_12_4_1 doi: 10.1056/NEJMoa1809866 – ident: e_1_2_12_31_1 doi: 10.15585/mmwr.mm6948a1 – ident: e_1_2_12_10_1 doi: 10.1002/jia2.25048 – ident: e_1_2_12_24_1 – ident: e_1_2_12_29_1 doi: 10.1111/j.0006-341X.2001.00120.x – ident: e_1_2_12_57_1 doi: 10.1002/jia2.26005 – ident: e_1_2_12_26_1 doi: 10.1016/S2352-3018(19)30190-0 – ident: e_1_2_12_28_1 doi: 10.1177/019251396017003001 – ident: e_1_2_12_15_1 doi: 10.1093/infdis/jiab021 – ident: e_1_2_12_25_1 doi: 10.1097/QAD.0000000000002989 – ident: e_1_2_12_8_1 – ident: e_1_2_12_14_1 doi: 10.1093/cid/ciaa413 – ident: e_1_2_12_27_1 doi: 10.1016/j.drugalcdep.2021.109005 – ident: e_1_2_12_6_1 – ident: e_1_2_12_7_1 doi: 10.1056/NEJMoa1702150 – ident: e_1_2_12_45_1 doi: 10.1371/journal.pone.0256865 – ident: e_1_2_12_51_1 doi: 10.1016/S2352-3018(20)30359-3 – volume: 25 issue: 3 year: 2022 ident: e_1_2_12_53_1 article-title: Population trends in HIV service delivery, viral suppression, and incidence before and during the COVID‐19 era in Rakai, Uganda publication-title: J Int AIDS Soc – ident: e_1_2_12_23_1 doi: 10.1016/S0140-6736(23)00877-2 – ident: e_1_2_12_13_1 doi: 10.1097/QAI.0000000000002508 – ident: e_1_2_12_48_1 doi: 10.1007/s10461-022-03582-z – ident: e_1_2_12_16_1 doi: 10.1016/S2352-3018(16)30034-0 – ident: e_1_2_12_42_1 doi: 10.1056/NEJMp1710608 – ident: e_1_2_12_34_1 doi: 10.1016/S2352-3018(19)30407-2 – reference: 37398460 - medRxiv. 2023 Jun 16:2023.06.15.23291445. doi: 10.1101/2023.06.15.23291445. |
SSID | ssj0062849 |
Score | 2.341707 |
Snippet | Introduction
Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are... Population-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We... Introduction: Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are... In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance... IntroductionPopulation-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are... Abstract Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in... |
SourceID | doaj proquest gale pubmed crossref wiley |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | e26200 |
SubjectTerms | AIDS (Disease) AIDS research Alcohol use Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs antiretroviral therapy Antiviral agents Apprenticeship Care and treatment Cohort analysis Cohort Studies Diagnosis Disease transmission Drug resistance Female HIV HIV infection HIV Infections - diagnosis HIV Infections - drug therapy HIV Infections - epidemiology HIV treatment HIV viraemia HIV-1 - genetics Households Housework Human immunodeficiency virus Humans Male Measurement Migration Patient outcomes Population Population studies Population-based studies prospective cohort Risk taking Self report Sexual behavior sub‐Saharan Africa Treat All Uganda - epidemiology Variables Viral Load Viremia Viremia - diagnosis Viremia - drug therapy Viremia - epidemiology |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELbQnpAQ4p_AAkYgkJDKJk5sJ9wKYtVdCU4t2ps1sZ1VUUir_ogrj8BD8SQ8CTN2GrUCwYVbFI_bxDMef-PMfGbsuVIN2AyDHMiVxQDFu1HtSxhJ7bTzVeWzmr7ofvioJrPi_EJe7B31RTlhkR44DtwJcVU2yisvG0IfWSW1LbQuvbYOchuidVzzdsFU9MEKnW41kJGKk89zEK-Jej09WH4CS__vvnhvMdoHrGHFOb3BrvdQkY_jI95kV3x3i12L-2w8lg_dZj-mkVuq5S6eLb_m0DnuViHfgi8a7rYrKo_ik7NPnDJ6W94uwPH1dtnnwHahx5I2zlDl3YYThfHPb9_D7XbxFS9bSi0Kvf2XOfBY28j7pA78xSm-TxCfEgbla1S8x27bJZ93fHZJuxVvOPDlcFoYNtL6iY9B9LZ32Oz0_fTdZNSfzDCykjIpHLgGJAhlZWMhz5QUqU1BF4UvtFO2yZzLMwspEKJrfFlXIBxCUZ0VzgHkd9lRt-j8fcYlOlhItYa6cUUtRelyK1zpU4AK_8El7NlOYWYZCThMpFoWhtRqgloT9pZ0OUgQaXa4gaZkelMy_zKlhD0hSzCxAnWY-masKwqcUy0S9jJI0OTfrMBCX8OAr0I0WgeSLw4kLyOJ-J8Ejw8EcXbbw-adWZreu6wNQjQMzBGrqoQ9HZqpJ2XMdX6xJRkMrCtVyDJh96I5D6OTl3lOFcsJexXs-y8Da87PxiJcPfgfQ_yQXRWICmPa-zE72qy2_hGiuk39OEzgX98WT5Y priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZguSAhxJvAAkYgkJCym6edcEEFsequBKcW9WZNPE5VFJLQh_hz_Dg8dhq2Au2tSsZJk_E8M_MNY6-FqEHHNsiBVGgboBgMK1NAmEuUaMrSxBV90f3yVUzn2cUiXwwJt81QVrnXiU5RY6cpR35qzZINRqx9Fh_6nyFNjaKvq8MIjevsBkGXUUmXXIwBl7CqtxwhSZPT7ytITgiAPTowQg6r_1-NfMkkXXZbnd05u8NuDw4jn3gO32XXTHuP3fLZNu6biO6z3zOPMNVw9BPmNxxa5Lh2VRe8qznu1tQkxafn3zjV9Ta86QD5ZtcPlbCtW9FT-swyvt1yAjIO3cGm-xU2VFzkVpofK-C-u5EPZR32ajP7LI54Rl4o31jWm3DX81XL50vKVrznwPtxWlhI1tPensBtH7D52efZp2k4zGUIdU51FAhYQw6J0HmtIY1FnkQ6ApllJpModB0jprGGCMifq01RlZCgdURlnCECpA_ZUdu15jHjuVWvEEkJVY1ZlScFpjrBwkQApb0DBuzVnlGq9_AbygMtJ4rYqRw7A_aReDhSEGS2O9Ctl2qQQEWgp7UwwuQ1ubF2u0idSVkYqRFSbS_ygnaA8v2no-CriSwpbI5kErC3joJEf7sGDUMHg30UAtE6oHxzQLn0EOL_Izw-ILSyrQ9P77ejGnTLRv2VhIC9HE_TSqqXa023IxobVpciy4uAPfLbeHw7aZGm1K8csHduX1_xYtXF-SRxv55c_U-espuJ9fZ8OfsxO9qud-aZ9da21XMnkn8AEb1AkQ priority: 102 providerName: ProQuest – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1fi9QwEA_H-SKInP_rnRpRFIT12rRJWvFlFY-9A8WHXbm3Mk3SZY-1XfYPvvoR_FB-Ej-JM0m3d4si-FaamW6b-ZOZ7MwvjD1XqgaTYJIDqTKYoDg7qFwOA6mttq4oXFLRP7ofP6nRJDs7l-d77O22FybgQ_QbbmQZ3l-TgUO1Or4EDb2YgXhNcOqYsF-j3lpCzhfZ560fVuh4C98OKVEXlBQ9OKk4vuTdWY48av-fvvnK4nQ1gPUr0MkBu9mFjnwYZH2L7bnmNrsR9t14aCe6w36OA9bUnNtw1vyKQ2O5Xfr6C97W3G6W1C7FR6dfOFX4zvm8BctXm0VXE9t4jgVtpKEKNGtOkMa_vv_wt-ftN7ycU6mR53ZfZ8BDryPvijzwiWP8Hk8-ppiUr1ARHLJtFnzW8MmUdi_ecOCL_vQwHKT1FF-D4G7vssnJh_H70aA7qWFgJFVWWLA1SBDKyNpAmuBsxyYGnWUu01aZOrE2TQzEQBFe7fKqAGExNNVJZi1Aeo_tN23jHjAu0eFCrDVUtc0qKXKbGmFzFwMU-As2Ys-2AisXAZCjDNDLoiSxll6sEXtHsuwpCETb32iX07KzyZJgUGvllJM1BbZJIbXJtM6dNhZSgw95QppQho7U3hWUQ11QIh1rEbGXnoKcwXoJBrqeBvwUgtXaoXyxQzkNoOJ_IzzaIURrN7vDW7UsO2-zKjFkw0QdY1cVsaf9MHFSBV3j2g3RYKJdqEzmEbsf1LmfnTRPU-pgjtgrr9__mNjy7HQo_NXD_yE-ZNcFRoOh3P2I7a-XG_cIo7l19dgb7W_h1Enw priority: 102 providerName: Wiley-Blackwell |
Title | Temporal dynamics and drivers of durable HIV viral load suppression and persistent high‐ and low‐level viraemia during Universal Test and Treat scale‐up in Uganda: a population‐based study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjia2.26200 https://www.ncbi.nlm.nih.gov/pubmed/38332519 https://www.proquest.com/docview/2931845606 https://www.proquest.com/docview/2924996458 https://doaj.org/article/0056f6e6e5f04561957c4778e7cda3c0 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ta9RAEF5q-0UQ8d1oPVcUBeHavG8iiFyl5VpoKXIpxS9hsrs5TmJy3gvqN3-CP8pf4i9xZjcX7rCIX-5CdjZ3uzuzM7OZeYaxF3FcgvTQyYEgluigaNUvdAL9SCihdJpqr6A3uqdn8TALTy6jyy22qt_ZTuD8SteO6klls2rv25fv71Dg37YAovufJuDvEbA6uu47qJEECehp2L1NiHELTk1iZIRcEUd-B1O63ndDMRn8_r936TU1tW7KGl10dIvdbI1IPrCrfptt6foOu2FP4LhNLLrLfo0s6lTFla06P-dQK65mJhKDNyVXyxklTvHh8QWnWN-KVw0oPl9O2-jY2vSY0pEaMkO94ARu_PvHT3O7ar7iZUVBR6a3_jwBbrMeeRvugU8c4XgM-YisUz5HltDYbTnlk5pnYzrHeMOBT7s6YthImhX_BgHf3mPZ0eHo_bDf1mzoy4hiLBSoEiLwYxmVEgIPZ9uVLogw1KFQsSw9pQJPggtk65U6KVLwFRqpwguVAgjus-26qfVDxiPcesEVAopShUXkJyqQvkq0C5DiLyiHPV8tWD610By5BWH2c1rW3Cyrww5oLTsKgtM2N5rZOG-lMydA1DLWsY5KMnG9NBIyFCLRQioIJD7kKXFCbnNTu00hH4iUXGpX-A57ZSiIURczkNBmN-BQCGBrg_LlBuXYwotfRbi7QYhyLzebV2yZr8QmR-MNXXa0YmOHPeuaqSfF0tW6WRINutxpHEaJwx5Ydu5mJ0iCgHKZHfba8Pc_JjY_OR745urR_47oMbvuo01og9532fZittRP0KZbFD12zQ_P8VNcih7bGVxkHzP8Pjg8O__QM-ckPSPSfwAUgFU9 |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELbK9gEkhLgJFGrEJSGFJs7hBAmhLbTa7SWEdlHfwsR2VouWJOyhij_FL-DH4bGT0BWob32LkrFzzHgOZ-YbQp7HcQHC10EOBLHQAYqSbq4ScCMuuVRpqvwc_-gen8SDcXhwGp1ukF9tLQymVbY60ShqWQncI9_RZkkHI9o-x-_rHy52jcK_q20LDSsWh-rnmQ7ZFu-GHzV_XzC2vzf6MHCbrgKuiDALQIIsIAIWi6gQEPhxxDzhAQ9DFXIZi8KXMvAFeIDeSKGSPAUmtRvF_VBKgEDPe4VshoEOZXpkc3fv5NPnVvfHWtmnHQgq2_k2BfYGId-9NbNnugP8awPOGcHzjrKxdPs3yY3GRaV9K1O3yIYqb5Prdn-P2rKlO-T3yGJazai0Pe0XFEpJ5dzkedCqoHI1x7IsOhh-oZhJPKOzCiRdrOom97Y0I2rcsNOiVi4pQie75uSsOnNnmM5kRqrvU6C2npI2iSR6tpF-F0M8Qr-XLrSwKXdV02lJxxPcH3lLgdZdfzIX7bW-PcLp3iXjS-HZPdIrq1I9IDTSCh08ziEvZJhHLJGBYDJRHkCq7yAd8qxlVFZbwI_MQjuzDNmZGXY6ZBd52FEgSLc5Uc0nWbPmM4RZLWIVq6hAx9lPIy5CzhPFhYRA6Em2UQIyW_HaqZqsz1MM1D3OHPLKUKCyWc5BQFMzoV8FYbvWKF-uUU4saPn_CLfWCLU2EeuXW3HMGm22yP6uPYc87S7jSMzQK1W1QhodyKdxGCUOuW_FuPs6QRIEWCHtkNdGri_4sNnBsM_M0cOLn2SbXB2Mjo-yo-HJ4SNyjWlf0ybTb5Hecr5Sj7WvuMyfNAuUkq-XrRP-AKwXgBI |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3rb9MwELfGkBASQrwJDGbES0IKTZzETpAQKoyq3WDiQzv1W7jaTlVUktCHJv41xB-Hz07DKtC-7VuUnJ3Hne_h3P2OkGecFyBDE-RAxKUJULTyJzoFPxFKKJ1lOpzgH93Px7w_ig_HyXiH_NrUwmBa5UYnWkWtKol75B1jlkwwYuwz7xRNWsSXg967-oePHaTwT-umnYYTkSP989SEb8u3gwPD6-eM9T4OP_T9psOALxPMCFCgCkiAcZkUEqKQJyyQAYg41rFQXBahUlEoIQD0TAqdTjJgyrhUIoyVAojMvJfIZRElIa4xMW6DPW7UftbCobLOtxmw1wj-HmwZQNsn4F9rcMYcnnWZrc3r3SDXG2eVdp103SQ7urxFrrmdPuoKmG6T30OHbjWnynW3X1IoFVULm_FBq4Kq9QILtGh_cEIxp3hO5xUoulzXTRZuaUfUuHVnhK5cUQRR9u3JeXXqzzGxyY7U32dAXWUlbVJKzGxD8y6WeIgeMF0asdP-uqazko6muFPyhgKt205lPlpuc3sE1r1DRhfCsbtkt6xKfZ_QxKh2CISASaHiScJSFUmmUh0AZOYOyiNPN4zKawf9kTuQZ5YjO3PLTo-8Rx62FAjXbU9Ui2nerP4cAVcLrrlOCnShwywRMhYi1UIqiKSZZB8lIHe1r63Sybsiw5A9EMwjLy0Fqp3VAiQ01RPmVRDAa4vyxRbl1MGX_49wb4vQ6BW5fXkjjnmj15b531XokSftZRyJuXqlrtZIY0L6jMdJ6pF7TozbrxOlUYS10h55ZeX6nA-bHw66zB49OP9J9skVownyT4Pjo4fkKjNOp8uq3yO7q8VaPzJO42ry2K5OSr5etDr4AwrwguI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Temporal+dynamics+and+drivers+of+durable+HIV+viral+load+suppression+and+persistent+high%E2%80%90+and+low%E2%80%90level+viraemia+during+Universal+Test+and+Treat+scale%E2%80%90up+in+Uganda%3A+a+population%E2%80%90based+study&rft.jtitle=Journal+of+the+International+AIDS+Society&rft.au=Rosen%2C+Joseph+Gregory&rft.au=Ssekubugu%2C+Robert&rft.au=Chang%2C+Larry+W&rft.au=Ssempijja%2C+Victor&rft.date=2024-02-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1758-2652&rft.eissn=1758-2652&rft.volume=27&rft.issue=2&rft_id=info:doi/10.1002%2Fjia2.26200&rft.externalDocID=A791061072 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-2652&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-2652&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-2652&client=summon |